Coronary Artery Bypass Grafting in Idiopathic Myelofibrosis: A Case Report
DOI:
https://doi.org/10.1532/HSF98.20061134Abstract
The concomitant presence of myeloproliferative disorders and the need for coronary artery bypass surgery is a surgical dilemma. Thrombosis and hemorrhage can cause difficult problems and might require different approaches during and after surgery. We report a patient who had idiopathic myelofibrosis and underwent a successful coronary artery bypass surgery.References
Deeb ME, Shargal Y, Merin G, Milgalter E. 2002. Incidental finding of myeloproliferative disorders during sternotomy. Ann Thorac Surg 73:1951-2.nDespotis GJ, Avidan MS, Hogue CW. 2001. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 72:1821-31.nEreth MH, Nuttall GA, Klindworth JT, et al. 1997. Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg 85:259-64.nFile TM Jr, Tan JS, Maseelall EA, Snyder RO. 1984. Recurrent cellulitis after bypass surgery associated with psoriasis. JAMA 252:1681.nGanti AK, Potti A, Koka VK, Pervez H, Mehdi SA. 2003. Myeloproliferative syndromes and the associated risk of coronary artery disease. Thromb Res 110:83-6.nSamuels LE, Kaufman MS, Kussmaul WG, Brockman SK. 1997. Pyoderma gangrenosum and myelofibrosis after coronary artery bypass grafting. J Thorac Cardiovasc Surg 113:795-7.nWehmeier A, Daum I, Jamin H, Schneider W. 1991. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. Ann Hematol 63:101-6.n
